Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

21.11
+1.567.98%
Post-market: 20.88-0.2300-1.09%17:04 EDT
Volume:768.09K
Turnover:16.08M
Market Cap:973.69M
PE:95.95
High:21.56
Open:19.68
Low:19.46
Close:19.55
52wk High:58.28
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:1.08
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2200
EPS(LYR):1.80
ROE:5.10%
ROA:-0.48%
PB:4.00
PE(LYR):11.73

Loading ...

U.S. Earnings Preview: After Market Close May 12

Dow Jones
·
May 13

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
May 12

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 12

Oddity Tech faces shareholder class action over alleged digital ad cost misstatements

Reuters
·
May 07

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewswire
·
May 07

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

Simply Wall St.
·
May 02

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Simply Wall St.
·
May 01

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire
·
Apr 30

Oddity price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions

Reuters
·
Apr 23

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

TIPRANKS
·
Apr 17

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian
·
Apr 17

Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures

Reuters
·
Apr 16

A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs

Simply Wall St.
·
Apr 11